Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results [Yahoo! Finance]
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: Yahoo! Finance
oral drug NBI-1117568 (NBI-'568) in adults with schizophrenia. The drug is being developed in partnership with Nxera Pharma (formerly Sosei Heptares). NBIX Reports Mixed Results The study met its primary endpoint — treatment with a 20 mg dose of NBI-'568 achieved a statistically significant and clinically meaningful 7.5-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score over placebo at week six. PANSS is a scale for measuring schizophrenia symptom severity. Though treatment with three other doses of the drug (30 mg, 40 mg and 60 mg) also achieved a reduction in PANSS scores ranging from 1.9 to 5.0 over placebo, they were not statistically significant. Treatment with the drug was safe and well-tolerated at all doses. Comparison With Peers However, Wall Street was not impressed with these results. Multiple analysts pointed out that the data did not match up with the previously-reported results on Bristol Myers ' BMY KarXT and AbbVie 's ABBV emracli
Show less
Read more
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.MarketBeat
- Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]Yahoo! Finance
- Stocks making the biggest moves after hours: Adobe, RH, Oracle and more [CNBC]CNBC
- Neurocrine Biosciences Provides Update on ERUDITE™ Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with SchizophreniaPR Newswire
- Neurocrine Biosciences to Participate at the 2024 Cantor Global Healthcare ConferencePR Newswire
NBIX
Earnings
- 8/1/24 - Beat
NBIX
Sec Filings
- 9/13/24 - Form 144
- 8/28/24 - Form 8-K
- 8/16/24 - Form 4
- NBIX's page on the SEC website